Management of JAK2-Positive Essential Thrombocythemia

Risk Stratification and Management

The National Comprehensive Cancer Network recommends risk-stratified management of JAK2-positive essential thrombocythemia, with low-dose aspirin (81-100 mg/day) for all patients and addition of cytoreductive therapy for high-risk patients (age >60 years with JAK2 mutation or history of thrombosis) 1, 2
Patients with JAK2-positive essential thrombocythemia are classified into four risk categories: very low risk (age ≤60 years, no JAK2 mutation, no prior thrombosis), low risk (age ≤60 years, JAK2 mutation positive, no prior thrombosis), intermediate risk (age >60 years, no JAK2 mutation, no prior thrombosis), and high risk (prior history of thrombosis and/or age >60 years with JAK2 mutation) 1, 3, 4
The presence of JAK2 mutation significantly increases thrombotic risk, particularly in patients over 60 years of age, with a thrombosis risk of approximately 1.59% in JAK2-positive patients without cardiovascular risk factors, increasing to 2.57% when cardiovascular risk factors are present 1

For low-risk JAK2-positive ET patients (age ≤60, no prior thrombosis), the recommended management includes monitoring for thrombosis, acquired von Willebrand disease, and disease-related bleeding, managing cardiovascular risk factors, and low-dose aspirin (81-100 mg/day) for vascular symptoms 5
For high-risk JAK2-positive ET patients (age >60 with JAK2 mutation or prior thrombosis), the recommended management includes low-dose aspirin (81-100 mg/day) and cytoreductive therapy with hydroxyurea, interferon alfa-2b, peginterferon alfa-2a, or peginterferon alfa-2b, or anagrelide 1, 7, 8

Patients with JAK2-positive essential thrombocythemia should be monitored for new thrombosis, acquired von Willebrand disease, and disease-related bleeding, and evaluated for signs of disease progression every 3-6 months 1, 2
The National Comprehensive Cancer Network recommends assessing for potential indications for cytoreductive therapy in initially low-risk patients, including symptomatic or progressive splenomegaly, symptomatic thrombocytosis, progressive leukocytosis, progressive disease-related symptoms, and vasomotor/microvascular disturbances not responsive to aspirin 1, 2, 5